NCT00854360

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Range-Finding Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Adult and Adolescent Patients (12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 487 (actual)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.

Conditions

• Seasonal Allergic Rhinitis
• Hayfever

Interventions

Type	Name	Description
DRUG	Beclomethasone dipropionate HFA Nasal Aerosol	Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
DRUG	Placebo	HFA Vehicle Aerosol

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2009-03-03
• Last updated: 2012-05-22
• Results posted: 2012-05-22

Locations

26 sites across 1 country: United States